Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
4726
YieldMax META Option Income Strategy ETF
FBY
$119M
| $31.5K | ﹤0.01% |
+2,500
| New | +$34.1K |
2025 Q4
0 quarters
|
|
4727
Children's Place
PLCE
$44.3M
| $31.2K | ﹤0.01% |
7,846
+7,407
| +1,687% | +$53.1K |
2025 Q3
1 quarter
|
|
4728
Culp Inc
CULP
$49.5M
| $31.1K | ﹤0.01% |
8,745
| – | – |
2016 Q3
37 quarters
|
|
|
SLN
4729
Silence Therapeutics
SLN
$661M
| $30.8K | ﹤0.01% |
5,065
-2,071
| -29% | -$13.3K |
2024 Q1
7 quarters
|
|
4730
Karyopharm Therapeutics
KPTI
$18.2M
| $30.2K | ﹤0.01% |
4,109
| – | – |
2013 Q4
48 quarters
|
|
4731
Innovator Buffer Step-Up Strategy ETF
BSTP
$59.5M
| $30K | ﹤0.01% |
807
-3,270
| -80% | -$120K |
2024 Q3
5 quarters
|
|
4732
Innovator US Equity Power Buffer ETF February
PFEB
$902M
| $29.9K | ﹤0.01% |
735
-1,699
| -70% | -$68.1K |
2025 Q2
2 quarters
|
|
4733
Caesarstone
CSTE
$96.1M
| $29.6K | ﹤0.01% |
15,932
| – | – |
2016 Q2
38 quarters
|
|
4734
Newegg Commerce
NEGG
$241M
| $29.6K | ﹤0.01% |
583
-1,152
| -66% | -$73.5K |
2022 Q2
14 quarters
|
|
4735
Village Farms International
VFF
$347M
| $29.4K | ﹤0.01% |
+8,060
| New | +$28.1K |
2025 Q4
0 quarters
|
|
4736
CI&T Inc
CINT
$411M
| $29.4K | ﹤0.01% |
7,228
| – | – |
2025 Q1
3 quarters
|
|
4737
The ONE Group
STKS
$49.4M
| $29.1K | ﹤0.01% |
16,657
| – | – |
2021 Q1
19 quarters
|
|
|
VNTG
4738
Vantage Corp
VNTG
$19.6M
| $28.9K | ﹤0.01% |
+33,210
| New | +$51.1K |
2025 Q4
0 quarters
|
|
4739
Trump Media & Technology Group
DJT
$2.48B
| $28.6K | ﹤0.01% |
2,159
+578
| +37% | +$7.89K |
2022 Q1
15 quarters
|
|
4740
Innovator US Equity Buffer ETF May
BMAY
$239M
| $28.4K | ﹤0.01% |
633
-3,537
| -85% | -$156K |
2024 Q3
5 quarters
|
|
4741
Brown-Forman Class A
BF.A
$12.2B
| $28.2K | ﹤0.01% |
1,073
+287
| +37% | +$8.01K |
2022 Q1
15 quarters
|
|
4742
Adecoagro
AGRO
$1.46B
| $28K | ﹤0.01% |
3,532
| – | – |
2025 Q2
2 quarters
|
|
4743
iShares MSCI India Small-Cap ETF
SMIN
$735M
| $28K | ﹤0.01% |
400
| – | – |
2023 Q4
8 quarters
|
|
4744
Ericsson
ERIC
$30.3B
| $27.9K | ﹤0.01% |
+2,890
| New | +$27.4K |
2025 Q4
0 quarters
|
|
4745
Nexa Resources
NEXA
$1.62B
| $27.7K | ﹤0.01% |
3,132
| – | – |
2023 Q3
9 quarters
|
|
|
CNTA
4746
DELISTED
Centessa Pharmaceuticals
CNTA
| $27.7K | ﹤0.01% |
1,108
-3,860
| -78% | -$97.8K |
2024 Q3
5 quarters
|
|
|
NEWP
4747
New Pacific Metals
NEWP
$1.17B
| $27.4K | ﹤0.01% |
+7,799
| New | +$21.3K |
2025 Q4
0 quarters
|
|
4748
GH Research
GHRS
$1.57B
| $26.9K | ﹤0.01% |
2,118
+822
| +63% | +$11.2K |
2025 Q3
1 quarter
|
|
4749
Innovator US Equity Accelerated Plus ETF October
XTOC
$15.9M
| $26.6K | ﹤0.01% |
794
-3,742
| -82% | -$123K |
2024 Q3
5 quarters
|
|
|
TSE
4750
DELISTED
Trinseo
TSE
| $26.5K | ﹤0.01% |
53,255
+5,273
| +11% | +$6.29K |
2022 Q1
15 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.